Related Experiment Videos
[Idiopathic portal hypertension].
H Orozco1, T Takahashi, G García-Tsao
1División de Cirugía, Clinica de Hipertensión Portal, Delegación Tlalpan, México, D.F.
Summary
Idiopathic portal hypertension (IPH) is a liver condition with unknown causes, characterized by fibrosis and vein obliteration. Surgical management offers better outcomes than sclerotherapy for preventing variceal bleeding in IPH patients without liver failure.
Area of Science:
- Hepatology and Gastroenterology
- Vascular Biology
- Pathology
Context:
- Idiopathic portal hypertension (IPH) encompasses various terms for liver conditions without a clear cause, frequently reported in India and Japan.
- Etiologies remain elusive, with proposed links to toxins, hepatitis B, immune issues, infections, and clotting disorders.
- Histopathology reveals periportal fibrosis and obliteration of small portal veins, potentially indicating primary vascular changes.
Purpose:
- To review the clinical presentation, histopathology, and management of idiopathic portal hypertension (IPH).
- To discuss the proposed etiologies and the primary site of increased resistance in IPH.
- To evaluate treatment options, including surgical and pharmacologic approaches, for managing variceal bleeding in IPH.
Summary:
- IPH presents with upper gastrointestinal bleeding from varices, anemia, and splenomegaly.
- The primary resistance to portal flow is presinusoidal, with some sinusoidal and postsinusoidal involvement.
- IPH patients demonstrate a better long-term prognosis (77% 10-year survival) than cirrhotic patients, with variceal bleeding being the main cause of mortality.
Impact:
- Surgical management is recommended as a primary elective treatment for IPH patients without liver failure due to high re-bleeding rates with sclerotherapy.
- Pharmacologic management may be considered for prophylactic treatment.
- Further research is needed to elucidate the etiology and optimize treatment strategies for IPH.